Form 4: Stoke Therapeutics Director Julie Smith Granted Significant Stock Options

Stoke Therapeutics, Inc. Director Julie Smith was granted 29,747 stock options with a strike price of $10.90, aligning her interests with shareholders.

Summary

• Julie Smith, a Director at Stoke Therapeutics, Inc. (STOK), received a grant of 29,747 Director Stock Options on June 3, 2025.
• The options have an exercise price of $10.90 per share and are set to expire on June 2, 2035.
• These options will vest in full on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, contingent upon Ms. Smith's continued service to the company.
• Following this transaction, Ms. Smith directly beneficially owns 29,747 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns the director's interests with shareholders and incentivizes long-term performance. It is a routine compensation event, not indicative of major operational changes or financial distress.

Positives

• The grant of stock options to a director helps align their financial interests with those of the company's shareholders, incentivizing long-term value creation.
• The vesting schedule encourages the director's continued commitment and service to the company.

Risks

• The value of the granted options is contingent on Stoke Therapeutics' stock price exceeding the exercise price of $10.90 in the future.
• The options are subject to forfeiture if the director's service to the issuer ceases before the vesting date.

Future Outlook

The document primarily details a past transaction (option grant) and its future vesting conditions, rather than providing a broad future outlook for the company's operations or financial performance.

Industry Context

The granting of stock options to directors is a common and standard practice within the biotechnology and broader public company sectors. It serves as a key component of executive and board compensation, designed to attract and retain talent while aligning their incentives with shareholder returns.

Comparison to Industry Standards

• Granting stock options to directors is a widely adopted compensation strategy across publicly traded companies, including those in the biotechnology industry.
• The specific size of the grant (29,747 options) and the exercise price ($10.90) would typically be evaluated against director compensation benchmarks of peer companies within the biotech sector to determine if it is competitive or exceptional. Without specific peer data, a direct comparison is not feasible from this document alone.

Related Party Transactions

• The grant of stock options to Julie Smith, a director, constitutes a related-party transaction, which is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholders, potentially leading to decisions that enhance shareholder value. However, it also represents potential future dilution if the options are exercised.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The 29,747 stock options are expected to vest on the earlier of June 3, 2026, or the date of Stoke Therapeutics' next annual meeting of stockholders, subject to continued service.
• Julie Smith may choose to exercise these options if Stoke Therapeutics' stock price rises above the $10.90 exercise price before the options expire on June 2, 2035.

Key Dates

Recommendation

Keywords

Stoke Therapeutics, STOK, SEC Form 4, stock options, director compensation, equity grant, insider transaction, corporate governance, biotechnology